Abbott Laboratories (NYSE:ABT) Price Target Lowered to $135.00 at Royal Bank Of Canada

Abbott Laboratories (NYSE:ABT) had its target price dropped by equities researchers at Royal Bank Of Canada from $147.00 to $135.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the healthcare product maker’s stock. Royal Bank Of Canada’s price objective would suggest a potential upside of 24.21% from the stock’s previous close.

A number of other research analysts have also weighed in on ABT. Raymond James Financial cut their target price on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a report on Friday. The Goldman Sachs Group dropped their price objective on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research note on Friday. Oppenheimer lowered their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a report on Friday. Weiss Ratings reissued a “buy (b-)” rating on shares of Abbott Laboratories in a research report on Monday, December 29th. Finally, Wells Fargo & Company boosted their target price on Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a research report on Thursday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $143.37.

Abbott Laboratories Stock Performance

Shares of NYSE ABT traded up $0.08 during trading on Friday, reaching $108.69. 2,307,181 shares of the stock traded hands, compared to its average volume of 8,972,974. The company has a 50-day moving average of $125.23 and a 200-day moving average of $128.54. Abbott Laboratories has a 52-week low of $105.78 and a 52-week high of $141.23. The stock has a market capitalization of $189.00 billion, a P/E ratio of 13.65, a price-to-earnings-growth ratio of 2.00 and a beta of 0.72. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. Abbott Laboratories’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Institutional Trading of Abbott Laboratories

A number of institutional investors and hedge funds have recently modified their holdings of ABT. Charles Schwab Trust Co lifted its holdings in Abbott Laboratories by 109.8% during the 3rd quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock valued at $3,939,000 after purchasing an additional 15,394 shares during the last quarter. Asset Management One Co. Ltd. boosted its holdings in shares of Abbott Laboratories by 2.4% in the 3rd quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock worth $115,032,000 after acquiring an additional 19,966 shares in the last quarter. Nordea Investment Management AB grew its position in Abbott Laboratories by 6.1% during the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock worth $43,785,000 after acquiring an additional 18,974 shares during the last quarter. Seaview Investment Managers LLC bought a new position in Abbott Laboratories in the 2nd quarter valued at $11,068,000. Finally, Eastern Bank grew its holdings in shares of Abbott Laboratories by 1.6% during the third quarter. Eastern Bank now owns 327,763 shares of the healthcare product maker’s stock worth $43,901,000 after purchasing an additional 5,294 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Several sell‑side analysts kept constructive ratings and still see meaningful upside — Piper Sandler cut its price target to $135 but remains “overweight,” and BTIG trimmed its target to $140 while keeping a “buy” call, signaling continued analyst confidence despite the pullback. Benzinga
• Positive Sentiment: Med tech (devices) and Established Pharmaceuticals delivered strong growth (double‑digit devices, mid‑single to high single pharma), which management says helped offset weakness in other segments and supports the company’s multi‑year growth thesis. Blockonomi
• Positive Sentiment: Market commentators view the pullback as a potential buying opportunity for long‑term investors because Abbott remains a cash‑generative Dividend King with capacity for buybacks and continued margin improvement. MarketBeat
• Neutral Sentiment: Adjusted EPS of $1.50 matched consensus, showing underlying earnings resilience even as revenues lagged; GAAP results included items that lowered headline net income. Press Release
• Neutral Sentiment: Company guidance: Q1 2026 adjusted EPS of $1.120–1.180 (below the ~1.20 consensus) and FY 2026 adjusted EPS of $5.55–5.80 (around consensus). Guidance tempered near‑term expectations but keeps mid/longer‑term growth intact. Press Release
• Negative Sentiment: Revenue missed Street estimates (~$11.46–11.5B reported vs. ~$11.8–11.9B expected); the Nutrition business declined sharply (near‑9% year‑over‑year) and Diagnostics weakened (lower COVID testing and volatility), which triggered the market sell‑off. Reuters Blockonomi
• Negative Sentiment: Unusual bearish positioning: intraday put option volume spiked sharply, indicating heavy hedging or speculative bearish bets that can amplify downward price moves. (Reported market activity)
• Negative Sentiment: Regulatory/legal overhang: documents show India regulators are scrutinizing supply of a codeine‑based cough syrup tied to abuse investigations, introducing potential reputational and compliance risk. Reuters

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.